HIGH-2-LOW模型的外部验证:异基因移植后静脉血栓栓塞的预测评分
在弗雷德·哈钦森癌症研究中心(FHCRC)和MD安德森癌症中心(MDACC)的异基因造血细胞移植(HCT)成人患者中,对HIGH-2-LOW风险评估模型进行时间与外部验证。FHCRC队列765例、MDACC队列954例,第180天静脉血栓栓塞(VTE)发生率分别为5.1%和6.8%。HIGH-2-LOW评分对VTE的c统计量在FHCRC为0.67(0.59-0.75)、在MDACC为0.62(0.55-0.70),高危组较低危组VTE的OR分别为2.80(1.46-5.38)和3.54(2.12-5.91)。
要点
- HIGH-2-LOW评分可识别异基因HCT后VTE高危患者。
- FHCRC队列第180天VTE发生率5.1%,MDACC队列6.8%。
- 高危(2分及以上)患者VTE风险升高,两队列OR分别为2.80和3.54。
核心结论
- HIGH-2-LOW风险评估模型在两个验证队列中均识别出异基因HCT后VTE高危患者,可改善移植后血栓预防的循证决策。
研究设计与样本
- 对近期推导的HIGH-2-LOW风险评估模型进行时间与外部验证研究。
- 纳入FHCRC和MDACC接受异基因HCT的成人患者,排除死亡、接受抗凝或第30天血小板未植入者。
- 主要结局为第180天总体VTE和肺栓塞±下肢深静脉血栓栓塞(PE/LE-DVT)。
- 协变量按原模型加权,但以2-4级移植物抗宿主病(GVHD)替代3-4级。
- 评估区分度和校准度。
主要发现
- FHCRC队列765例,MDACC队列954例。
- 第180天VTE发生率FHCRC为5.1%,MDACC为6.8%。
- HIGH-2-LOW评分对VTE的c统计量FHCRC为0.67(0.59-0.75),MDACC为0.62(0.55-0.70)。
- 对PE/LE-DVT的c统计量FHCRC为0.75(0.64-0.81),MDACC为0.70(0.56-0.83)。
- 高危(2分及以上)患者比例FHCRC为25%,MDACC为23%;高危较低危VTE的OR在FHCRC为2.80(1.46-5.38),在MDACC为3.54(2.12-5.91);PE/LE-DVT的OR在FHCRC为4.21(1.82-9.77),在MDACC为6.82(2.30-20.16)。
临床怎么用
- 原文结论认为HIGH-2-LOW风险评估模型可改善移植后血栓预防的循证决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In patients undergoing hematopoietic cell transplantation (HCT), venous thromboembolism (VTE) remains a serious complication that lacks validated risk assessment models (RAMs) to guide thromboprophylaxis. To address this dilemma, we performed a temporal and external validation study of the recently derived HIGH-2-LOW RAM. We selected adult patients undergoing allogeneic HCT from Fred Hutchinson Cancer Research Center (FHCRC) and MD Anderson Cancer Center (MDACC). Patients who died, received anticoagulation, or did not engraft platelets by day 30 were excluded. Primary outcomes were defined as overall VTE and pulmonary embolism ± lower-extremity deep venous thromboembolism (PE/LE-DVT) by day 180. Covariates were weighted according to the original model, except that grade 2-4 GVHD was substituted for grade 3-4. Discrimination and calibration were assessed. A total of 765 patients from FHCRC and 954 patients from MDACC were included. Incident VTE by day 180 was 5.1% at FHCRC and 6.8% at MDACC. The HIGH-2-LOW score had a c-statistic of 0.67 (0.59-0.75) for VTE and 0.75 (0.64-0.81) for PE/LE-DVT at FHCRC and 0.62 (0.55-0.70) for VTE and 0.70 (0.56-0.83) for PE/LE-DVT at MDACC. Twenty-five percent and 23% of patients were classified as high risk (2+ points) in the two cohorts, respectively. High versus low-risk was associated with odds ratio (OR) of 2.80 (1.46-5.38) for VTE and 4.21 (1.82-9.77) for PE/LE-DVT at FHCRC and OR of 3.54 (2.12-5.91) for VTE and 6.82 (2.30-20.16) for PE-LE-DVT at MDACC. The HIGH-2-LOW RAM identified allogeneic HCT recipients at high risk for VTE in both validation cohorts. It can improve evidence-based decision-making for thromboprophylaxis post-transplant.
引用
- Li A, Martens KL, Nguyen D, et al. External validation of the HIGH-2-LOW model: A predictive score for venous thromboembolism after allogeneic transplant. Am J Hematol. 2022. PMID: 35266218. doi:10.1002/ajh.26521
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。